Loading clinical trials...

Lymph Node Ratio and Kras Mutation in R Colon Cancer | Clinical Trials | Clareo Health

Back to search

COMPLETEDPHASE3

Lymph Node Ratio and Kras Mutation in R Colon Cancer

Lymph Node Ratio and Kras Mutation in Risk Stratification of Colon Cancer

NCT04342676•Mansoura University

View on ClinicalTrials.gov

Summary

clinical impact of LN ratio with Kras expression in colon cancer

Detailed Description

LNR and K ras were evaluated with correlated with different clinicopathological parameters of the patients, PFS and OS.

Eligibility

Age

16 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Stage III colon cancer

Exclusion Criteria

•Stage I, II, IV

Locations (1)

Mansoura University Oncology Center

Al Mansurah, Dakahlia Governorate, Egypt

Key Dates

Start Date

March 10, 2017

Primary Completion Date

August 25, 2019

Completion Date

August 26, 2019

Last Updated

April 13, 2020

Enrollment

433

ACTUAL participants

Conditions

Colon Cancer Stage III

Interventions

k ras

DEVICE

Panitumumab

DRUG

Survival Outcomes by Tumor-Node Stage and Recurrence Patterns in Colon Cancer After Radical Surgery

NCT07167147

Colon CancerColon Adenocarcinoma+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 13, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions